Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

Nour K. Majbour, Nishant N. Vaikath, Karin D. van Dijk, +11

Molecular Neurodegeneration

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Oskar Hansson, Sara Hall, Annika Öhrfelt, +9

Alzheimer s Research & Therapy

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration

Megan F. Duffy, Timothy J. Collier, Joseph R. Patterson, +13

Journal of Neuroinflammation

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice

Mantia Karampetsou, Mustafa T. Ardah, Maria Semitekolou, +7

Scientific Reports

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity

Simona S. Ghanem, Nour K. Majbour, Nishant N. Vaikath, +18

Proceedings of the National Academy of Sciences

Serine 129Molecular BiologySynaptic SignalingSocial Sciencesα-Synuclein Phosphorylation +18

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

Lucilla Parnetti, Lucia Farotti, Paolo Eusebi, +10

Frontiers in Aging Neuroscience

Neurochemical BiomarkersSynaptic SignalingSocial SciencesNeurobiology Of DiseaseDegenerative Pathology +16

Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression

Nour K. Majbour, Nishant N. Vaikath, Paolo Eusebi, +9

Movement Disorders

Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology

Nishant N. Vaikath, Nour K. Majbour, Katerina E. Paleologou, +14

Neurobiology of Disease

Neurodegenerative DiseasesImmunologyMolecular BiologyProtein MisfoldingAntibody Engineering +2

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial

Dieter Volc, Werner Poewe, Alexandra Kutzelnigg, +13

The Lancet Neurology

Neurodegenerative DiseasesAutoimmune DiseaseImmunologyNeurologyImmunotherapy +2

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies

Inger van Steenoven, Nour K. Majbour, Nishant N. Vaikath, +6

Movement Disorders